Skip to Main Content

Paper Details

Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.
Blood Rev
15
2022
Author NameAffiliation
Michael W DeiningerVersiti Blood Research Institute
Jorge CortesGeorgia Cancer Center
  • 1 - 2

Datasets

Release 1.2